Back to JPMORGAN CHASE & CO JPMORGAN CHASE & CO

MLTXMLTX
7 quarters

Position history for JPMORGAN CHASE & COJPMORGAN CHASE & CO's holdings in MOONLAKE IMMUNOTHERAPEUTICS

JPMORGAN CHASE & CO holds 1.4M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), worth $27.6M as of 2026-Q2. The position was increased (+27.4% shares). MLTX represents 0.0% of JPMORGAN CHASE & CO's portfolio.

Current Value

$27.6M

Current Shares

1.4M

Total Value Change

+$27.5M

Total Shares Change

+1.4M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.4M
+27.4%
$27.6M0.0%$19.47
36
2026-Q1
Increased
1.1M
+29.9%
$18.4M0.0%$17.69
36
2025-Q4
Increased
837,739
+140.5%
$11M0.0%$13.21
45
2025-Q3
Increased
348,322
+784.1%
$2.5M0.0%$6.24
42
2025-Q2
Increased
39,397
+4584.5%
$1.9M0.0%$47.52
42
2025-Q1
Decreased
841
-32.7%
$32,8580.0%$39.86
0
2024-Q4
New
1,250
-
$67,6870.0%$53.02
32

Other major holders of MLTX: FMR LLC, Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used